Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
57% of patients treated with Imfinzi were alive at three years in ADRIATIC Phase III trial.Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT). These results will be presented today during the Plenary Session at